SG186219A1 - Direct cloning - Google Patents
Direct cloning Download PDFInfo
- Publication number
- SG186219A1 SG186219A1 SG2012090056A SG2012090056A SG186219A1 SG 186219 A1 SG186219 A1 SG 186219A1 SG 2012090056 A SG2012090056 A SG 2012090056A SG 2012090056 A SG2012090056 A SG 2012090056A SG 186219 A1 SG186219 A1 SG 186219A1
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- acid molecule
- rece
- linear
- homologous recombination
- Prior art date
Links
- 238000010367 cloning Methods 0.000 title claims description 68
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 323
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 317
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 317
- 238000000034 method Methods 0.000 claims abstract description 210
- 238000002744 homologous recombination Methods 0.000 claims abstract description 130
- 230000006801 homologous recombination Effects 0.000 claims abstract description 130
- 108020004414 DNA Proteins 0.000 claims description 186
- 108090000623 proteins and genes Proteins 0.000 claims description 133
- 210000004027 cell Anatomy 0.000 claims description 128
- 239000013598 vector Substances 0.000 claims description 87
- 108091034117 Oligonucleotide Proteins 0.000 claims description 76
- 108010068698 spleen exonuclease Proteins 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 230000014509 gene expression Effects 0.000 claims description 60
- 230000001404 mediated effect Effects 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 238000001727 in vivo Methods 0.000 claims description 49
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 102000004190 Enzymes Human genes 0.000 claims description 42
- 108090000790 Enzymes Proteins 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 42
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 40
- 238000000137 annealing Methods 0.000 claims description 38
- 239000013599 cloning vector Substances 0.000 claims description 38
- 238000005520 cutting process Methods 0.000 claims description 38
- 239000002299 complementary DNA Substances 0.000 claims description 36
- 230000001939 inductive effect Effects 0.000 claims description 33
- 108010055016 Rec A Recombinases Proteins 0.000 claims description 29
- 102000001218 Rec A Recombinases Human genes 0.000 claims description 29
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 26
- 210000000349 chromosome Anatomy 0.000 claims description 24
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 19
- 238000004520 electroporation Methods 0.000 claims description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 108091008053 gene clusters Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 101150061231 recE gene Proteins 0.000 claims description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 6
- 229930000044 secondary metabolite Natural products 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000004136 fatty acid synthesis Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 238000005215 recombination Methods 0.000 description 109
- 230000006798 recombination Effects 0.000 description 106
- 239000013612 plasmid Substances 0.000 description 67
- 239000000047 product Substances 0.000 description 61
- 241000588724 Escherichia coli Species 0.000 description 48
- 102000053602 DNA Human genes 0.000 description 33
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 26
- 101150038013 PIR gene Proteins 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 108020004682 Single-Stranded DNA Proteins 0.000 description 22
- 230000006698 induction Effects 0.000 description 21
- 239000003550 marker Substances 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 230000009466 transformation Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 16
- 229930027917 kanamycin Natural products 0.000 description 16
- 229960000318 kanamycin Drugs 0.000 description 16
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 16
- 229930182823 kanamycin A Natural products 0.000 description 16
- 238000007792 addition Methods 0.000 description 15
- 239000013613 expression plasmid Substances 0.000 description 15
- 230000010076 replication Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 241001646716 Escherichia coli K-12 Species 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 101150102092 ccdB gene Proteins 0.000 description 10
- 108060002716 Exonuclease Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102000013165 exonuclease Human genes 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108010091086 Recombinases Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 6
- 102000018120 Recombinases Human genes 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 101150079601 recA gene Proteins 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 5
- 241001148064 Photorhabdus luminescens Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 101100386214 Bacillus subtilis (strain 168) dabA gene Proteins 0.000 description 3
- 101100012155 Escherichia coli (strain K12) exoD gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229930189065 blasticidin Natural products 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000008519 endogenous mechanism Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 101150022010 gam gene Proteins 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101100365003 Mus musculus Scel gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 101150023497 mcrA gene Proteins 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101150024821 tetO gene Proteins 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100402795 Caenorhabditis elegans mtl-1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010046914 Exodeoxyribonuclease V Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001523412 Heterorhabditis bacteriophora Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- 101150109417 NRPS gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- 241001148062 Photorhabdus Species 0.000 description 1
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 101150043283 ccdA gene Proteins 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150106284 deoR gene Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000967 entomopathogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108700010833 lambda phage proteins Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- -1 merBC Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 1
- 101150012154 nupG gene Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 101150059159 proA2 gene Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150087770 recT gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 101150047315 sbcC gene Proteins 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/16—Exonucleases active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters (3.16)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1009732.7A GB201009732D0 (en) | 2010-06-10 | 2010-06-10 | Direct cloning |
| PCT/IB2011/052549 WO2011154927A2 (en) | 2010-06-10 | 2011-06-10 | Direct cloning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG186219A1 true SG186219A1 (en) | 2013-01-30 |
Family
ID=42471456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012090056A SG186219A1 (en) | 2010-06-10 | 2011-06-10 | Direct cloning |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10443051B2 (enExample) |
| EP (2) | EP2580338B1 (enExample) |
| JP (2) | JP5934196B2 (enExample) |
| CN (2) | CN103068995B (enExample) |
| CA (1) | CA2802167C (enExample) |
| GB (1) | GB201009732D0 (enExample) |
| SG (1) | SG186219A1 (enExample) |
| WO (1) | WO2011154927A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| EP2612918A1 (en) * | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
| CN102558309B (zh) * | 2012-02-10 | 2014-09-17 | 浙江大学 | 一对转录激活子样效应因子核酸酶及其编码基因与应用 |
| CN102627691B (zh) * | 2012-04-05 | 2014-09-17 | 浙江大学 | 一对转录激活子样效应因子核酸酶及其编码基因与应用 |
| CN104364380B (zh) | 2012-04-25 | 2018-10-09 | 瑞泽恩制药公司 | 核酸酶介导的使用大靶向载体的靶向 |
| CN102702335B (zh) * | 2012-05-23 | 2014-07-09 | 上海斯丹赛生物技术有限公司 | 重组转录激活子样效应因子、转录激活子样效应因子核酸酶及其编码基因及应用 |
| CN105209601A (zh) | 2012-10-16 | 2015-12-30 | 基因桥有限责任公司 | 电感受态细胞及其制备 |
| CA2908697C (en) | 2013-04-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| SG10201700961TA (en) | 2013-12-11 | 2017-04-27 | Regeneron Pharma | Methods and compositions for the targeted modification of a genome |
| EP3083958B1 (en) * | 2013-12-19 | 2019-04-17 | Amyris, Inc. | Methods for genomic integration |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| MX384887B (es) | 2014-06-23 | 2025-03-14 | Regeneron Pharma | Ensamblaje de adn mediado por nucleasa. |
| EP3161128B1 (en) | 2014-06-26 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| CN105713885B (zh) * | 2014-12-04 | 2019-06-11 | 清华大学 | 特异识别并修复β地中海贫血症beta-globin基因的嵌合核酸酶 |
| JP6840077B2 (ja) | 2014-12-19 | 2021-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物 |
| CN105734061B (zh) * | 2016-03-25 | 2019-07-23 | 中国农业科学院生物技术研究所 | 从毕赤酵母中分离的鼠李糖诱导型启动子及其应用 |
| CN109715813A (zh) * | 2016-04-06 | 2019-05-03 | 基因桥有限公司 | 腺病毒载体 |
| CN106995813B (zh) * | 2017-03-23 | 2020-06-16 | 山东大学 | 基因组大片段直接克隆和dna多分子组装新技术 |
| CN109385417A (zh) * | 2017-08-03 | 2019-02-26 | 华东理工大学 | 体内dna无缝组装方法 |
| CA3136114A1 (en) * | 2019-04-05 | 2020-10-08 | Danisco Us Inc. | Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof |
| CN110184287B (zh) * | 2019-05-24 | 2024-01-30 | 华南农业大学 | 一种制备重组病毒的方法及其应用 |
| MX2021014861A (es) | 2019-06-25 | 2022-06-22 | Inari Agriculture Tech Inc | Edicion genomica de reparacion dependiente de homologia mejorada. |
| CN115717152A (zh) * | 2022-11-29 | 2023-02-28 | 江南大学 | 一种控制枯草芽孢杆菌基因组同源重组概率的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| US5776744A (en) | 1995-06-07 | 1998-07-07 | Yale University | Methods and compositions for effecting homologous recombination |
| AU752105B2 (en) * | 1997-12-05 | 2002-09-05 | Europaisches Laboratorium Fur Molekularbiologie (Embl) | Novel dna cloning method |
| AUPP684998A0 (en) | 1998-10-30 | 1998-11-26 | Murdoch Institute for Research into Birth Defects Limited, The | A method of recombination and agents useful for same |
| US6355412B1 (en) * | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
| US6569681B1 (en) * | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| US20040101520A1 (en) | 2001-02-09 | 2004-05-27 | Muijrers Joep P P | Recombination method |
| EP1409702A1 (en) | 2001-07-20 | 2004-04-21 | Youming Zhang | Improved rect or recet cloning and subcloning method |
| WO2004067753A2 (en) * | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| WO2007013979A2 (en) | 2005-07-20 | 2007-02-01 | Invitrogen Corporation | Methods for increasing efficiency of homologous recombination |
| KR100681815B1 (ko) * | 2005-12-02 | 2007-02-12 | 한국생명공학연구원 | 리컴비네이즈 매개 선택표지 유전자 발현유도에 의한 목표유전자 간편 클로닝 및 목표 단백질 신속 발현 방법. |
| US10407672B2 (en) | 2006-03-27 | 2019-09-10 | Seattle Children's Hospital | Compositions and methods comprising the use of cell surface displayed homing endonucleases |
| GB0803109D0 (en) | 2008-02-20 | 2008-03-26 | Gene Bridges Gmbh | Method of nucleic acid recombination |
| JP2011217736A (ja) * | 2010-03-26 | 2011-11-04 | Aichi Medical Univ | 組換えクラミジア及びその製造方法 |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
-
2010
- 2010-06-10 GB GBGB1009732.7A patent/GB201009732D0/en not_active Ceased
-
2011
- 2011-06-10 CA CA2802167A patent/CA2802167C/en active Active
- 2011-06-10 US US13/806,086 patent/US10443051B2/en active Active
- 2011-06-10 SG SG2012090056A patent/SG186219A1/en unknown
- 2011-06-10 JP JP2013513806A patent/JP5934196B2/ja active Active
- 2011-06-10 EP EP11729474.4A patent/EP2580338B1/en active Active
- 2011-06-10 CN CN201180038908.6A patent/CN103068995B/zh active Active
- 2011-06-10 EP EP16192084.8A patent/EP3138921A1/en not_active Withdrawn
- 2011-06-10 WO PCT/IB2011/052549 patent/WO2011154927A2/en not_active Ceased
- 2011-06-10 CN CN201810875866.5A patent/CN109825486A/zh active Pending
-
2016
- 2016-05-06 JP JP2016093169A patent/JP2016135158A/ja active Pending
-
2019
- 2019-09-06 US US16/563,274 patent/US12195732B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200283759A1 (en) | 2020-09-10 |
| US20130210681A1 (en) | 2013-08-15 |
| WO2011154927A2 (en) | 2011-12-15 |
| JP2013530689A (ja) | 2013-08-01 |
| JP2016135158A (ja) | 2016-07-28 |
| US10443051B2 (en) | 2019-10-15 |
| US12195732B2 (en) | 2025-01-14 |
| CA2802167C (en) | 2023-03-07 |
| CA2802167A1 (en) | 2011-12-15 |
| EP2580338B1 (en) | 2016-10-05 |
| WO2011154927A9 (en) | 2013-01-24 |
| CN103068995B (zh) | 2020-10-16 |
| CN103068995A (zh) | 2013-04-24 |
| JP5934196B2 (ja) | 2016-06-15 |
| EP2580338A2 (en) | 2013-04-17 |
| CN109825486A (zh) | 2019-05-31 |
| WO2011154927A3 (en) | 2012-02-16 |
| GB201009732D0 (en) | 2010-07-21 |
| EP3138921A1 (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12195732B2 (en) | Direct cloning | |
| US10287590B2 (en) | Methods for generating libraries with co-varying regions of polynuleotides for genome modification | |
| Akhmetov et al. | Single-step precision genome editing in yeast using CRISPR-Cas9 | |
| CN106995813B (zh) | 基因组大片段直接克隆和dna多分子组装新技术 | |
| EP1291420B1 (en) | Novel DNA cloning method relying on the E.coli RECE/RECT recombination system | |
| EP2255001B1 (en) | Method of nucleic acid recombination | |
| Muyrers et al. | ET-cloning: think recombination first | |
| US20230183678A1 (en) | In-cell continuous target-gene evolution, screening and selection | |
| CN115552002A (zh) | 基因组改造方法及基因组改造试剂盒 | |
| WO2024081738A2 (en) | Compositions, methods, and systems for dna modification | |
| JP2004535773A (ja) | 組換え法 | |
| WO2010113031A2 (en) | Method of altering nucleic acids | |
| US20240052370A1 (en) | Modulating cellular repair mechanisms for genomic editing | |
| WO2010140066A2 (en) | Method of altering nucleic acids | |
| Muijrers | ET recombination, a novel DNA engineering strategy |